Zentalis Pharmaceuticals, Inc. (ZNTL): Free Cash Flow
-$125.25M
Year ended 2025-12-31
-$128.13M
Trailing 12 months to 2026-06-30
| Period ended | Free Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$125.25M | n/m | 2026-03-26, From 2025-01-01 |
| 2024-12-31 | -$171.08M | n/m | 2026-03-26, From 2024-01-01 |
| 2023-12-31 | -$208.41M | n/m | 2026-03-26, From 2023-01-01 |
| 2022-12-31 | -$166.30M | n/m | 2025-03-26, From 2022-01-01 |
| 2021-12-31 | -$160.20M | n/m | 2024-02-27, From 2021-01-01 |
| 2020-12-31 | -$87.58M | n/m | 2023-03-01, From 2020-01-01 |
| 2019-12-31 | -$39.49M | n/a | 2022-02-24, From 2019-01-01 |
Free Cash Flow at similar companies
| Company | Year ended | Free Cash Flow | Change YoY |
|---|---|---|---|
| Zentalis Pharmaceuticals, Inc. (ZNTL) | 2025-12-31 | -$125.25M | n/m |
| Abbott Laboratories (ABT) | 2025-12-31 | $7.39B | +16.4% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $12.85B | -7.9% |
| Pfizer Inc (PFE) | 2025-12-31 | $9.07B | -7.7% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $19.70B | -0.7% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $28.84M | +101.3% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $12.36B | -31.7% |
| Lisata Therapeutics, Inc. (LSTA) | 2025-12-31 | -$15.98M | n/m |
| Heron Therapeutics, Inc. (HRTX) | 2025-12-31 | -$27.91M | n/m |
Compare ZNTL, ABT, BMY, PFE side by side · Screen every company in Pharmaceutical Preparations ↗